The
new weight loss pill Belviq ( lorcaserin hydrochloride ) , the
pharmaceutical company Arena has been recently approved by the FDA . This is the first drug for weight loss long term that has been approved by the Food and Drug Administration in 13 years. Belviq
works by activating serotonin 2C receptor in the brain that may help
you eat less by the feeling of fullness after small meals . When
used with a combination of a balanced diet and exercise, this
requirement helps people lose about 5 % or more of their starting weight
.
According to Janet Woodcock , director of FDA's Center for Drug Evaluation and Research , "Obesity threatens the welfare of patients and is a major public health problem . Approval of this drug , used responsibly, in combination with a healthy diet and lifestyle , provides a treatment option for Americans who are obese "or overweight patients and other weight-related diseases such as hypertension , type 2 diabetes or high cholesterol.
Adults contain a body mass index (BMI ) of 27 or greater (overweight ) are approved for the drug should be available in the first quarter of 2013 . It is also for adults who are obese , with a BMI of 30 or more.
About 36 percent of U.S. adults are obese, which is about 30 kilos more at a healthy weight . Those extra pounds increase the risk of heart disease , type 2 diabetes , stroke , many other types of cancer, sleep apnea and other debilitating diseases and chronic sleep . There are about 42 percent of adults are projected to be obese by 2030 if nothing is done to reverse the trend.
There were three randomized, placebo-controlled, containing about 8,000 overweight or obese patients with and without type 2 diabetes treated for 52-104 weeks. These assays were used to evaluate the efficacy and safety of Belviq . The results show that people who took Belviq for at least 12 months had an average weight loss of 3% to 3.7 % .
Will be mandatory for drug manufacturers to conduct six post- marketing studies , including a test of cardiovascular morbidity and mortality in the long run to evaluate the effect of Belviq risk of adverse cardiac events , such as stroke and stroke the heart. Valve evaluated cardiac function by echocardiography approximately 8000 patients in the Belviq development program .
The FDA says that people with congestive heart failure should exercise caution when using this drug , as it has not been studied in patients with severe valvular disease . Belviq weight loss pill can cause problems with memory or attention . The FDA also states that lorcaserin not be used during pregnancy.
According to the Food and Drug Administration, no " statistically significant difference between lorcaserin and placebo -treated patients . "
In 1997 , weight loss drugs fenfluramine and dexfenfluramine were taken from the market after it found evidence that they caused damage to heart valves . The effect is supposed to be related to the activation of the serotonin 2B receptor in heart disease . When used with the approved 10 mg twice daily dose , Belviq does not appear to activate the serotonin 2B receptor .
Weight loss pill Belviq approved a label recommends that patients discontinue use if they fail to lose 5 % of their body weight after 3 months , as these patients are unlikely to achieve much weight loss with the use continuous , according to the FDA.
The most common side effects of Belviq in nondiabetic patients include dizziness , headache , fatigue , dry mouth , nausea and constipation , and patients with diabetes are hypoglycemia , back pain , fatigue , cough and headache .
According to Janet Woodcock , director of FDA's Center for Drug Evaluation and Research , "Obesity threatens the welfare of patients and is a major public health problem . Approval of this drug , used responsibly, in combination with a healthy diet and lifestyle , provides a treatment option for Americans who are obese "or overweight patients and other weight-related diseases such as hypertension , type 2 diabetes or high cholesterol.
Adults contain a body mass index (BMI ) of 27 or greater (overweight ) are approved for the drug should be available in the first quarter of 2013 . It is also for adults who are obese , with a BMI of 30 or more.
About 36 percent of U.S. adults are obese, which is about 30 kilos more at a healthy weight . Those extra pounds increase the risk of heart disease , type 2 diabetes , stroke , many other types of cancer, sleep apnea and other debilitating diseases and chronic sleep . There are about 42 percent of adults are projected to be obese by 2030 if nothing is done to reverse the trend.
There were three randomized, placebo-controlled, containing about 8,000 overweight or obese patients with and without type 2 diabetes treated for 52-104 weeks. These assays were used to evaluate the efficacy and safety of Belviq . The results show that people who took Belviq for at least 12 months had an average weight loss of 3% to 3.7 % .
Will be mandatory for drug manufacturers to conduct six post- marketing studies , including a test of cardiovascular morbidity and mortality in the long run to evaluate the effect of Belviq risk of adverse cardiac events , such as stroke and stroke the heart. Valve evaluated cardiac function by echocardiography approximately 8000 patients in the Belviq development program .
The FDA says that people with congestive heart failure should exercise caution when using this drug , as it has not been studied in patients with severe valvular disease . Belviq weight loss pill can cause problems with memory or attention . The FDA also states that lorcaserin not be used during pregnancy.
According to the Food and Drug Administration, no " statistically significant difference between lorcaserin and placebo -treated patients . "
In 1997 , weight loss drugs fenfluramine and dexfenfluramine were taken from the market after it found evidence that they caused damage to heart valves . The effect is supposed to be related to the activation of the serotonin 2B receptor in heart disease . When used with the approved 10 mg twice daily dose , Belviq does not appear to activate the serotonin 2B receptor .
Weight loss pill Belviq approved a label recommends that patients discontinue use if they fail to lose 5 % of their body weight after 3 months , as these patients are unlikely to achieve much weight loss with the use continuous , according to the FDA.
The most common side effects of Belviq in nondiabetic patients include dizziness , headache , fatigue , dry mouth , nausea and constipation , and patients with diabetes are hypoglycemia , back pain , fatigue , cough and headache .
